Free tool
FAERS Monitor: Epkinly
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761324 or its brand name (Epkinly, Epcoritamab-Bysp). Reports on generic versions are filed under their own applications.
Reports
1,338
Serious
1,237
92% of reports
Hospitalization
316
Death reported
442
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cytokine release syndrome463
- diffuse large b-cell lymphoma251
- diffuse large b-cell lymphoma refractory235
- pyrexia148
- immune effector cell-associated neurotoxicity syndrome108
- malignant neoplasm progression104
- neutrophil count decreased58
- cytomegalovirus infection reactivation56
- covid-1954
- platelet count decreased45
- hypogammaglobulinaemia43
- pneumonia39
- death38
- cytomegalovirus infection36
- off label use31
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 104 |
| 2024 | 580 |
| 2025 | 410 |
| 2026 | 244 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,821 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| diffuse large b-cell lymphoma refractorySignal | 235 | 5193.3 | 4526.7 | 913,359 |
| diffuse large b-cell lymphomaSignal | 251 | 529.3 | 472.3 | 127,573 |
| cytokine release syndromeSignal | 463 | 371.4 | 344.6 | 166,880 |
| immune effector cell-associated neurotoxicity syndromeSignal | 108 | 291.9 | 243.2 | 30,466 |
| cytomegalovirus infection reactivationSignal | 56 | 201.8 | 155.9 | 10,853 |
| hypogammaglobulinaemiaSignal | 43 | 103.6 | 77.1 | 4,239 |
| cytomegalovirus infectionSignal | 36 | 34.1 | 24.7 | 1,123 |
| neutrophil count decreasedSignal | 58 | 22.4 | 17.4 | 1,165 |
| malignant neoplasm progressionSignal | 104 | 16.0 | 13.3 | 1,451 |
| pyrexiaSignal | 148 | 6.7 | 5.8 | 727 |
| platelet count decreasedSignal | 45 | 6.6 | 5.0 | 211 |
| covid-19Signal | 54 | 4.8 | 3.7 | 162 |
| pneumonia | 39 | 1.9 | 1.4 | 16 |
| death | 38 | 0.7 | 0.5 | 5 |
| off label use | 31 | 0.6 | 0.4 | 11 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.